登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 案件所处的诉讼阶段：原告撤诉。 ● 上市公司所处当事人地位：上海泰坦科技股份有限公司（以下简称"公 一、诉讼案件的基本情况 2025年5月，公司收到上海市普陀区人民法院送达的《民事传票》〔案号：（2025）沪0107民初9533 号〕及《民事起诉状》等相关诉讼材料。上海跃胜贸易有限公司起诉公司，认为公司和安徽天地侵犯其 独家代理权。具体内容详见公司于2025年5月披露的《关于公司及控股子公司涉及诉讼的公告》（公告 编号：2025-024）。 二、案件最新进展情况 公司于近日收到上海市普陀区人民法院送达的《民事裁定书》[（2025）沪 0107民初9533号之一]。原告 上海跃胜贸易有限公司向上海市普陀区人民法院提出撤诉申请，法院准许上海跃胜贸易有限公司撤诉。 三、本次诉讼对公司的影响 本次原告撤诉不会对公司的日常生产经营产生负面影响，也不会对公司当期及未来的损益产生负面影 响。 司"）及控股子公司安徽天地高 ...

证券代码：688133 证券简称：泰坦科技 公告编号：2026-002 上海泰坦科技股份有限公司 关于公司及控股子公司诉讼进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 案件所处的诉讼阶段：原告撤诉。 2025 年 5 月，公司收到上海市普陀区人民法院送达的《民事传票》〔案号： （2025）沪 0107 民初 9533 号〕及《民事起诉状》等相关诉讼材料。上海跃胜贸 易有限公司起诉公司，认为公司和安徽天地侵犯其独家代理权。具体内容详见公 司于 2025 年 5 月披露的《关于公司及控股子公司涉及诉讼的公告》（公告编号： 2025-024）。 二、案件最新进展情况 公司于近日收到上海市普陀区人民法院送达的《民事裁定书》[（2025）沪 0107 民初 9533 号之一]。原告上海跃胜贸易有限公司向上海市普陀区人民法院 1 提出撤诉申请，法院准许上海跃胜贸易有限公司撤诉。 三、本次诉讼对公司的影响 上市公司所处当事人地位：上海泰坦科技股份有限公司（以下简称"公 司"）及控股子公司安徽天地高纯溶剂有限 ...

资金面上，2月9日融资买入736.34万元，融资偿还553.47万元，融资净买入182.86万元，融资余额为2.48 亿元，反映市场做多情绪短期强化。主力资金近3日净流出1287.48万元，显示短期资金面承压。 以上内容基于公开资料整理，不构成投资建议。 经济观察网 泰坦科技（688133）近7天股价呈现波动走势。根据行情数据，2月5日股价下跌1.59%至 24.68元，2月6日微涨0.16%至24.72元，2月9日上涨2.75%至25.40元，2月10日下跌1.54%至25.01元，2月 11日下跌0.60%至24.86元，区间累计跌幅0.88%。2月12日开盘后最新股价为25.15元，较前一日上涨 1.17%。 资金面情况 ...

Core Viewpoint - The article analyzes the 2025 performance forecasts of 22 domestic listed instrument companies, highlighting the divergence in performance and the impact of various market factors on the industry [2]. Group 1: Industry Overview - The overall operating conditions of the domestic instrument industry are gradually becoming clearer as companies disclose their 2025 performance forecasts [2]. - Among the 22 companies, 11 reported profits while 11 incurred losses; 8 of the profitable companies experienced year-on-year growth, while 3 saw stable or slightly fluctuating profits [2]. - The performance divergence is attributed to factors such as fluctuations in downstream demand, intensified industry competition, policy changes, and global supply chain instability [2]. Group 2: Performance Statistics - The net profit statistics for the listed instrument companies indicate significant growth for several firms, with some achieving over 190% year-on-year increases [3][8]. - Notable performers include: - Aiko Optoelectronics: Net profit of 0.57-0.7 billion, up 262.52-345.20% from 0.1572 billion [3]. - Haineng Technology: Net profit of 0.41-0.44 billion, up 213.65-236.61% from 0.1307 billion [3]. - Wan Yi Technology: Net profit of 0.42-0.62 billion, up 191.52-330.34% from 0.1441 billion [3]. Group 3: Industry Trends - The industry is witnessing increased performance divergence, with a trend towards higher concentration as companies with core technologies and strategic layouts capture more market share [5]. - The ongoing domestic substitution is deepening, with high-end instruments becoming a key growth driver, supported by policy incentives for high-end scientific instruments and equipment upgrades [5]. - Companies focusing on high-end sectors, such as high-end industrial imaging and clinical diagnostics, are expected to benefit from these trends [5]. Group 4: Operational Strategies - Companies facing operational pressures are likely to improve performance by divesting loss-making businesses, optimizing asset structures, and enhancing management of receivables and inventory [6]. - Profit-making companies will continue to pursue refined management practices to consolidate their advantages and enhance risk resilience [6]. Group 5: Performance Categories - Companies achieving profit growth or turning losses into profits are primarily benefiting from asset impairment improvements and business structure optimizations [18]. - The companies in this category include: - Gaode Infrared: Successfully turned around from a loss to a profit [18]. - Xianhe Environmental: Achieved profitability through structural optimization [21]. - Zhengye Technology: Also turned from loss to profit due to similar improvements [22]. Group 6: Challenges Faced - Companies experiencing expanded losses or transitioning from profit to loss share common challenges, including reliance on single business lines and significant asset impairment pressures [30]. - The need for transformation is evident, as some companies are in the process of adjusting their business models, which may not yet yield sufficient revenue to offset declines in traditional business areas [30].

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

南方财经1月29日电，泰坦科技(688133.SH)公告，预计2025年年度实现归属于母公司所有者的净利润 为-1800万元至-1200万元，预计实现归属于母公司所有者扣除非经常性损益后的净利润为-7500万元 至-5500万元。上年同期归属于母公司所有者的净利润为1,289.29万元，归属于母公司所有者的扣除非经 常性损益的净利润为572.09万元。 公司在经营中进行了业务结构调整，舍弃了部分业务，使得营业收入出现下滑，虽毛利率有所提升，但 毛利额仍略有下降。同时，虽然费用有所控制，但新增固定资产投入使用带来的折旧摊销增长较多，导 致利润总额下降。经过初步评估测算，本年度商誉减值预计约2800万元，四季度新增存货跌价预计约 2400万元，导致扣非净利润降幅较大。 ...

证券日报网讯 1月28日，泰坦科技发布公告称，公司预计2025年年度实现归属于母公司所有者的净利润 将出现亏损，金额预计为-1800万元至-1200万元；预计2025年年度实现归属于母公司所有者扣除非经常 性损益后的净利润为-7500万元至-5500万元。 （编辑 丛可心） ...

智通财经APP讯，泰坦科技(688133.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润将出现亏损，金额预计为-1800万元至-1200万元。 ...

泰坦科技(688133.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利润将出现亏损， 金额预计为-1800万元至-1200万元。 ...

（记者 曾健辉） 每经头条（nbdtoutiao）——从极寒测试到万套装车！半固态电池今年有望搭载多款新车：各大厂商摩 拳擦掌，动力电池技术迎来迭代年 每经AI快讯，泰坦科技1月28日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 将出现亏损，金额预计为-1800万元至-1200万元。业绩变动主要原因是，公司在经营中进行了业务结构 调整，舍弃了部分业务，使得营业收入出现下滑，虽毛利率有所提升，但毛利额仍略有下降。同时，虽 然费用有所控制，但新增固定资产投入使用带来的折旧摊销增长较多，导致利润总额下降。经过初步评 估测算，本年度商誉减值预计约2800万，四季度新增存货跌价预计约2400万，导致扣非净利润降幅较 大。 ...